|
Gene: SLC25A5 |
Gene summary for SLC25A5 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SLC25A5 | Gene ID | 292 |
Gene name | solute carrier family 25 member 5 | |
Gene Alias | 2F1 | |
Cytomap | Xq24 | |
Gene Type | protein-coding | GO ID | GO:0000422 | UniProtAcc | P05141 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
292 | SLC25A5 | GSM4909282 | Human | Breast | IDC | 1.72e-91 | 7.74e-01 | -0.0288 |
292 | SLC25A5 | GSM4909285 | Human | Breast | IDC | 3.62e-33 | 5.55e-01 | 0.21 |
292 | SLC25A5 | GSM4909286 | Human | Breast | IDC | 1.46e-08 | -1.30e-01 | 0.1081 |
292 | SLC25A5 | GSM4909287 | Human | Breast | IDC | 4.02e-02 | -2.84e-01 | 0.2057 |
292 | SLC25A5 | GSM4909292 | Human | Breast | IDC | 5.48e-05 | -7.79e-01 | 0.1236 |
292 | SLC25A5 | GSM4909293 | Human | Breast | IDC | 2.49e-12 | -3.55e-01 | 0.1581 |
292 | SLC25A5 | GSM4909294 | Human | Breast | IDC | 1.36e-10 | -2.46e-01 | 0.2022 |
292 | SLC25A5 | GSM4909296 | Human | Breast | IDC | 2.82e-23 | 1.29e-01 | 0.1524 |
292 | SLC25A5 | GSM4909297 | Human | Breast | IDC | 1.29e-29 | -3.74e-01 | 0.1517 |
292 | SLC25A5 | GSM4909298 | Human | Breast | IDC | 6.78e-10 | -2.90e-01 | 0.1551 |
292 | SLC25A5 | GSM4909301 | Human | Breast | IDC | 7.92e-15 | -4.64e-01 | 0.1577 |
292 | SLC25A5 | GSM4909302 | Human | Breast | IDC | 2.02e-03 | -2.79e-01 | 0.1545 |
292 | SLC25A5 | GSM4909306 | Human | Breast | IDC | 6.88e-04 | 2.85e-01 | 0.1564 |
292 | SLC25A5 | GSM4909308 | Human | Breast | IDC | 7.66e-04 | 3.00e-01 | 0.158 |
292 | SLC25A5 | GSM4909309 | Human | Breast | IDC | 2.93e-04 | -2.76e-01 | 0.0483 |
292 | SLC25A5 | GSM4909311 | Human | Breast | IDC | 5.42e-60 | -5.35e-01 | 0.1534 |
292 | SLC25A5 | GSM4909312 | Human | Breast | IDC | 1.79e-14 | -6.07e-04 | 0.1552 |
292 | SLC25A5 | GSM4909313 | Human | Breast | IDC | 1.12e-02 | -2.08e-01 | 0.0391 |
292 | SLC25A5 | GSM4909315 | Human | Breast | IDC | 1.57e-14 | -4.73e-01 | 0.21 |
292 | SLC25A5 | GSM4909316 | Human | Breast | IDC | 7.80e-05 | -4.13e-01 | 0.21 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00300984 | Esophagus | ESCC | lymphocyte differentiation | 192/8552 | 374/18723 | 1.52e-02 | 4.93e-02 | 192 |
GO:000989612 | Liver | Cirrhotic | positive regulation of catabolic process | 215/4634 | 492/18723 | 1.13e-20 | 3.56e-18 | 215 |
GO:003133112 | Liver | Cirrhotic | positive regulation of cellular catabolic process | 190/4634 | 427/18723 | 1.94e-19 | 4.18e-17 | 190 |
GO:200123312 | Liver | Cirrhotic | regulation of apoptotic signaling pathway | 163/4634 | 356/18723 | 2.62e-18 | 4.43e-16 | 163 |
GO:00224117 | Liver | Cirrhotic | cellular component disassembly | 182/4634 | 443/18723 | 1.59e-14 | 1.54e-12 | 182 |
GO:001623611 | Liver | Cirrhotic | macroautophagy | 129/4634 | 291/18723 | 1.75e-13 | 1.41e-11 | 129 |
GO:20012347 | Liver | Cirrhotic | negative regulation of apoptotic signaling pathway | 102/4634 | 224/18723 | 8.40e-12 | 5.60e-10 | 102 |
GO:00068397 | Liver | Cirrhotic | mitochondrial transport | 112/4634 | 254/18723 | 1.03e-11 | 6.66e-10 | 112 |
GO:001050611 | Liver | Cirrhotic | regulation of autophagy | 132/4634 | 317/18723 | 2.17e-11 | 1.33e-09 | 132 |
GO:19030084 | Liver | Cirrhotic | organelle disassembly | 59/4634 | 114/18723 | 4.82e-10 | 2.27e-08 | 59 |
GO:00070065 | Liver | Cirrhotic | mitochondrial membrane organization | 57/4634 | 116/18723 | 1.13e-08 | 4.29e-07 | 57 |
GO:00004225 | Liver | Cirrhotic | autophagy of mitochondrion | 43/4634 | 81/18723 | 4.02e-08 | 1.31e-06 | 43 |
GO:00617265 | Liver | Cirrhotic | mitochondrion disassembly | 43/4634 | 81/18723 | 4.02e-08 | 1.31e-06 | 43 |
GO:00108216 | Liver | Cirrhotic | regulation of mitochondrion organization | 62/4634 | 144/18723 | 1.09e-06 | 2.22e-05 | 62 |
GO:00159316 | Liver | Cirrhotic | nucleobase-containing compound transport | 87/4634 | 222/18723 | 1.25e-06 | 2.52e-05 | 87 |
GO:003009912 | Liver | Cirrhotic | myeloid cell differentiation | 135/4634 | 381/18723 | 1.69e-06 | 3.22e-05 | 135 |
GO:00162414 | Liver | Cirrhotic | regulation of macroautophagy | 60/4634 | 141/18723 | 2.57e-06 | 4.63e-05 | 60 |
GO:00106397 | Liver | Cirrhotic | negative regulation of organelle organization | 124/4634 | 348/18723 | 3.20e-06 | 5.60e-05 | 124 |
GO:00973455 | Liver | Cirrhotic | mitochondrial outer membrane permeabilization | 20/4634 | 32/18723 | 6.64e-06 | 1.04e-04 | 20 |
GO:00086377 | Liver | Cirrhotic | apoptotic mitochondrial changes | 47/4634 | 107/18723 | 1.10e-05 | 1.57e-04 | 47 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501218 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0502016 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
hsa0501616 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
hsa0501016 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0520818 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
hsa0541518 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
hsa0501714 | Breast | Precancer | Spinocerebellar ataxia | 29/684 | 143/8465 | 2.79e-06 | 3.83e-05 | 2.94e-05 | 29 |
hsa042189 | Breast | Precancer | Cellular senescence | 29/684 | 156/8465 | 1.66e-05 | 1.69e-04 | 1.30e-04 | 29 |
hsa0516618 | Breast | Precancer | Human T-cell leukemia virus 1 infection | 33/684 | 222/8465 | 4.29e-04 | 3.31e-03 | 2.53e-03 | 33 |
hsa0501219 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0502017 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
hsa0501617 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
hsa0501017 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0520819 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
hsa0541519 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
hsa0501715 | Breast | Precancer | Spinocerebellar ataxia | 29/684 | 143/8465 | 2.79e-06 | 3.83e-05 | 2.94e-05 | 29 |
hsa0421814 | Breast | Precancer | Cellular senescence | 29/684 | 156/8465 | 1.66e-05 | 1.69e-04 | 1.30e-04 | 29 |
hsa0516619 | Breast | Precancer | Human T-cell leukemia virus 1 infection | 33/684 | 222/8465 | 4.29e-04 | 3.31e-03 | 2.53e-03 | 33 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC25A5 | insertion | Frame_Shift_Ins | novel | c.249_250insA | p.Thr84AsnfsTer5 | p.T84Nfs*5 | P05141 | protein_coding | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
SLC25A5 | SNV | Missense_Mutation | novel | c.618N>T | p.Lys206Asn | p.K206N | P05141 | protein_coding | deleterious(0.05) | benign(0.033) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SLC25A5 | SNV | Missense_Mutation | c.858N>G | p.Phe286Leu | p.F286L | P05141 | protein_coding | tolerated(1) | benign(0.003) | TCGA-C5-A2M2-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
SLC25A5 | SNV | Missense_Mutation | novel | c.839N>A | p.Arg280Lys | p.R280K | P05141 | protein_coding | deleterious(0.01) | possibly_damaging(0.532) | TCGA-C5-A8XJ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |
SLC25A5 | SNV | Missense_Mutation | c.439N>G | p.Lys147Glu | p.K147E | P05141 | protein_coding | deleterious(0) | possibly_damaging(0.488) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD | |
SLC25A5 | SNV | Missense_Mutation | c.317G>T | p.Arg106Ile | p.R106I | P05141 | protein_coding | deleterious(0.01) | benign(0.015) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
SLC25A5 | SNV | Missense_Mutation | c.91N>T | p.Arg31Trp | p.R31W | P05141 | protein_coding | tolerated(0.09) | benign(0.209) | TCGA-CM-6678-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD | |
SLC25A5 | SNV | Missense_Mutation | c.703N>T | p.Arg235Cys | p.R235C | P05141 | protein_coding | deleterious(0.05) | possibly_damaging(0.835) | TCGA-D5-6541-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
SLC25A5 | SNV | Missense_Mutation | novel | c.288N>T | p.Lys96Asn | p.K96N | P05141 | protein_coding | deleterious(0.02) | probably_damaging(0.979) | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
SLC25A5 | SNV | Missense_Mutation | c.703C>T | p.Arg235Cys | p.R235C | P05141 | protein_coding | deleterious(0.05) | possibly_damaging(0.835) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
292 | SLC25A5 | DRUGGABLE GENOME, TRANSPORTER | CLODRONATE | CLODRONIC ACID | ||
292 | SLC25A5 | DRUGGABLE GENOME, TRANSPORTER | TRICHOSTATIN A | 10657244 | ||
292 | SLC25A5 | DRUGGABLE GENOME, TRANSPORTER | BUTYRATE | 10657244 |
Page: 1 |